

Successful Completion of Less Than Marketable Parcel Share Sale Program

September 18th 2017. Melbourne, Australia.

- **425 less than marketable parcels (“LTMP”) sold, representing 436,120 shares;**
- **Participating shareholders to receive 18.0 cents per share;**
- **Shareholder base reduced to approximately 1,250 shareholders.**

Rhinomed Limited (ASX: RNO or “the Company”) is pleased to announce that it has completed the sale of shares for holders of less than marketable parcels (LTMP) in the Company.

A total of 425 shareholders, with an aggregate of 436,120 shares participated in the program. The shares were sold on market at a price of 18.0 cents per share (being the market closing price on the sale date of 5 September 2017). It is anticipated that the proceeds are to be distributed to participants during the week commencing 11 September 2017.

RNO Ordinary Fully Paid Shares Holding Range as at 5 September 2017:

| Holding Ranges | Holders | Total Units | % Issued Share Capital |
|--------------------------|--------------|-------------------|------------------------|
| 1 - 1,000 | 61 | 12,700 | 0.01% |
| 1,001 - 5,000 | 275 | 1,026,472 | 1.10% |
| 5,001 - 10,000 | 249 | 2,076,404 | 2.22% |
| 10,001 - 100,000 | 548 | 18,769,584 | 20.05% |
| 100,101 - 9,999,999,9991 | 115 | 71,751,999 | 76.63% |
| Totals | 1,248 | 93,637,159 | 100.00% |

Following the LTMP sale, based on the market closing price on the sale date of 5 September 2017, the number of holders with an unmarketable holding is 108 with a total of 104,993 shares (0.11% of issued capital).

RHINOMED

MAKE EVERY BREATH COUNT

The table below shows the post LTMP issued capital position of the Company

| Issued Securities | | Quantity | | Exercise Price | Expiration Date |
|---------------------|------|-------------------|------------------|----------------|-----------------|
| Class of Securities | | Shares | Options | | |
| Listed Shares | | 93,637,159 | | | |
| Unlisted Options | ESOP | | 6,000,000 | \$0.27 | 30 April 2020 |
| Unlisted Options | ESOP | | 150,000 | \$0.40 | 30 Dec 2020 |
| Unlisted Options | ESOP | | 1,800,000 | \$0.665 | 11 Apr 2019 |
| Unlisted Options | | | 76,923 | \$0.65 | 30 Apr 2019 |
| Unlisted Options | | | 1,000,000 | \$0.67 | 30 Apr 2019 |
| Totals | | 93,637,159 | 9,026,923 | | |

The table below shows the details of the substantial holders of the Company.

| Holder Name | Holding | Voting Power (%) |
|-----------------------------------|------------|------------------|
| W.Whitney George | 16,570,121 | 17.70% |
| Ron Dewhurst and related entities | 7,184,680 | 7.67% |

Follow us on **Twitter** @rhinomedceo @mutesnoring @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global